Please login to the form below

Not currently logged in

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

Takeda says the consultation over the proposed closure of its operations in Cambridge, UK is continuing with no decisions made.Takeda pharma building

The company told PMLiVE that local news reports indicating the closure was already agreed, and that the process would complete before the end of the year, were premature.

Takeda Cambridge is being affected by the company's decision to focus its R&D operations in Japan and the US, part of a sweeping restructuring campaign initiated by the Japanese group's first western chief executive Christophe Weber.

Earlier this year, Weber implemented a $275m plan to streamline Takeda's R&D on core areas - oncology, gastroenterology and the central nervous system plus vaccines - around a Japanese centre in Shonan and US centres in San Diego and Boston.  

It is not clear yet how many jobs may be lost if the unit is closed, as some of the R&D being carried out at Cambridge remains within Takeda's focus, with projects covering Alzheimer's disease and schizophrenia as well as diabetes, obesity and inflammatory diseases.

Takeda has been operating in Cambridge since its 2007 acquisition of TCB, a drug discovery company set up by Cambridge University researchers.  The company also operates a European development centre in London that employs 400 people.

The company has said the R&D revamp is needed to provide "organisational and financial flexibility to drive innovation, enhance partnerships and improve R&D productivity for long-term sustainable growth".

The restructuring at Takeda has also seen its older generic drugs bundled into a joint venture with Teva and the sale of its respiratory business to AstraZeneca, something that also goes against perceived wisdom in the Japanese pharma industry where mature branded products are generally viewed as a valued asset.

Earlier this month it also announced plans to offload a majority stake in Wako Pure Chemical in a deal that could bring in around $1bn and help fund an ongoing campaign to bolster its pipeline via licensing deals and acquisitions.

Article by
Phil Taylor

26th August 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...